A Global Open-label Extension Study to Observe the Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial
Latest Information Update: 13 Feb 2025
At a glance
- Drugs SerpinPC (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Therapeutic Use
- Acronyms PRESent-6
- Sponsors ApcinteX
- 10 Feb 2025 Status changed from recruiting to discontinued due to business and strategic decision.
- 26 Aug 2024 New trial record